Several patients were also on insulin, sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, and SGLT2 inhibitors, reflecting the progressive and multifaceted treatment needs of type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.